Precigen, Inc. is a commercial-stage biopharmaceutical company that develops precision medicines for difficult-to-treat diseases with high unmet patient needs. The company is known for its FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). Precigen focuses on advancing treatments using non-replicating adenoviral vector-based immunotherapy.
